All in all, these findings suggest that targeting the interaction of Rab18 and VSIG4 could contribute to marked efficacy in glioma while provides novel sights for understanding the pathogenesis of glioma and developing new therapeutical methods. Here, VSIG4 is linked to central nervous system cancer.